Stevanato Group S.p.a. Stock
€18.30
Your prediction
Stevanato Group S.p.a. Stock
Pros and Cons of Stevanato Group S.p.a. in the next few years
Pros
Cons
News
![Stevanato Group Reports Financial Results for the Second Quarter of 2024: https://mms.businesswire.com/media/20220601006234/en/1474001/5/JPG_Logo_SG_RGB.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM2lTV0E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--b2f041e985c928ae88be33159fcbf865323db61c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/JPG_Logo_SG_RGB.jpg?locale=us)
Stevanato Group Reports Financial Results for the Second Quarter of 2024
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today
![Stevanato Group to Report Second Quarter 2024 Financial Results on August 6, 2024: https://mms.businesswire.com/media/20220601006234/en/1474001/5/JPG_Logo_SG_RGB.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM2lTV0E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--b2f041e985c928ae88be33159fcbf865323db61c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/JPG_Logo_SG_RGB.jpg?locale=us)
Stevanato Group to Report Second Quarter 2024 Financial Results on August 6, 2024
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries
![Stevanato Group Appoints Franco Stevanato Chief Executive Officer, Succeeding Franco Moro: https://mms.businesswire.com/media/20240528385017/en/2142378/5/F_Stevanato.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMGltYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5e4bde5175157dcc036d77e5baa3e71a4c17cf2b/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/F_Stevanato.jpg?locale=us)
Stevanato Group Appoints Franco Stevanato Chief Executive Officer, Succeeding Franco Moro
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries